Galecto Inc - Asset Resilience Ratio
Galecto Inc (GLTO) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Galecto Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how Galecto Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Galecto Inc.
Liquid Assets Composition Over Time
This chart breaks down Galecto Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Galecto Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Galecto Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Galecto Inc Industry Peers by Asset Resilience Ratio
Compare Galecto Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.11% |
|
Viking Therapeutics Inc
NASDAQ:VKTX |
Biotechnology | 75.44% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 0.91% |
|
CureVac NV
F:5CV |
Biotechnology | 0.27% |
|
Replimune Group Inc
NASDAQ:REPL |
Biotechnology | 43.82% |
Annual Asset Resilience Ratio for Galecto Inc (2020–2024)
The table below shows the annual Asset Resilience Ratio data for Galecto Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $17.13 Million | -- |
| 2023-12-31 | 30.57% | $11.69 Million | $38.23 Million | -6.92pp |
| 2022-12-31 | 37.49% | $27.44 Million | $73.19 Million | +6.70pp |
| 2021-12-31 | 30.79% | $37.63 Million | $122.22 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $171.60 Million | -- |
About Galecto Inc
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The comp… Read more